Article
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.
Clinical lung cancer - 1 Jul 2024
Mills Matthew N, Uno Akihiro, Li Pinxue, Liveringhouse Casey, Kim Youngchul, Oliver Daniel E, Perez Bradford A, Creelan Benjamin C, Yu Michael, Forsyth Peter A, Pina Yolanda, Ahmed Kamran A
Abstract excerpt
BACKGROUND: EGFR-targeted therapy (ETT) and immune-checkpoint blockade (ICB) have shown promising results in treating NSCLC brain metastases (BM). However, little is known of their effect in treating leptomeningeal disease (LMD). PATIENTS AND METHODS: This is a retrospective review of 80 patients diagnosed with NSCLC LMD from January 2014 to March 2021. Patients were grouped based on initial LMD treatment:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.